Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia

Leukemia

Volumn 25, Issue 5, 2011, Pages 808-813

  Craddock, C ^a   Labopin, M ^b   Pillai, S ^a   Finke, J ^c   Bunjes, D ^d   Greinix, H ^e   Ehninger, G ^f   Steckel, N K ^g   Zander, A R ^h   Schwerdtfeger, R ⁱ   Buchholz, S ^j   Kolb, H J ^k   Volin, L ^l   Fauser, A ^m   Polge, E ^b   Schmid, C ⁿ   Mohty, M ^b,o   Rocha, V ^b,p  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

ⁱ DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m Klinik fur Knochenmarktransplantation und Hamatologie/Onkologie GmbH   (Germany)

ⁿ II Medizinische Klinik Klinikum   (Germany)

^o NANTES UNIVERSITY HOSPITAL   (France)

^p SAINT LOUIS HOSPITAL   (France)

more..

Author keywords

acute myeloid leukaemia; Primary refractory; unrelated donor transplantation

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGRAFT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DONOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTION; PRIMARY REFRACTORY ACUTE GRANULOCYTIC LEUKEMIA; PRIORITY JOURNAL; REFRACTORY PERIOD; SCORING SYSTEM; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SURVIVAL TIME; UNRELATED DONOR TRANSPLANTATION;

ADOLESCENT; ADULT; AGED; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LIVING DONORS; MALE; MIDDLE AGED; REMISSION INDUCTION; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79955795186     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2011.13     Document Type: Article

References (22)

1. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a southwest oncology group/eastern cooperative oncology group study. Blood 2000; 13: 4075-4083.
2. Frohling S, Schlenk RF, Kayser S, Morhardt M, Benner A, Dohner K et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood 2006; 10: 3280-3288.
3. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The medical research council adult and children's leukaemia working parties. Blood 1998; 7: 2322-2333. (Pubitemid 28452973)
4. Revesz D, Chelghoum Y, Le QH, Elhamri M, Michallet M, Thomas X. Salvage by timed sequential chemotherapy in primary resistant acute myeloid leukemia: analysis of prognostic factors. Ann Hematol 2003; 11: 684-690. (Pubitemid 37460966)
5. Fung HC, Stein A, Slovak M, O'Donnell MR, Snyder DS, Cohen S et al. A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome. Biol Blood Marrow Transplant 2003; 12: 766-771. (Pubitemid 38145746)
6. Biggs JC, Horowitz MM, Gale RP, Ash RC, Atkinson K, Helbig W et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 4: 1090-1093.
7. Michallet M, Thomas X, Vernant JP, Kuentz M, Socie G, Esperou-Bourdeau H et al. Long-term outcome after allogeneic hemato-poietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM). Bone Marrow Transplant 2000; 11: 1157-1163.
8. Mehta J, Powles R, Horton C, Milan S, Treleaven J, Tait D et al. Bone marrow transplantation for primary refractory acute leukaemia. Bone Marrow Transplant 1994; 3: 415-418. (Pubitemid 24295236)
9. Schetelig J, Bornhauser M, Schmid C, Hertenstein B, Schwerdtfeger R, Martin H et al. Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from The Cooperative German Transplant Study Group. J Clin Oncol 2008; 26: 5183-5191.
10. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloabla-tive conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 12: 2304-2312. (Pubitemid 41748028)
11. Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood 2006; 3: 1092-1099. (Pubitemid 44154650)
12. Kaplan E, Meier P. Non-parametric estimates from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
13. Klein JP, Rizzo JD, Zhang MJ, Keiding N. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone marrow transplant 2001; 10: 909-915. (Pubitemid 33130231)
14. Cox D. Regression models and life tables. J R Stat Soc B 1972; 34: 197-220.
15. Sorror ML, Sandmeier BM, Store BE, Maris MB, Baron F, Maloney DG et al. Comorbidity and disease status risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic stem cell transplantation. J Clin Oncol 2007; 20: 4246-4254. (Pubitemid 47554249)
16. Yakoub-Agha I, Mesnil F, Kuentz M, Boiron JM, Ifrah N, Milpied N et al. Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy: a prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy. J Clin Oncol 2006; 36: 5695-5702. (Pubitemid 46631311)
17. Behrendt CE, Rosenthal J, Bolotin E, Nakamura R, Zaia J, Forman SJ. Donor and recipient CMV serostatus and outcome of pediatric allogeneic HSCT for acute leukemia in the era of CMV-preemptive therapy. Biol Blood Marrow Transplant 2009; 1: 54-60.
18. Jacobsen N, Badsberg JH, Lonnqvist B, Ringden O, Volin L, Rajantie J et al. Graft-versus-leukaemia activity associated with CMV-seropositive donor, post-transplant CMV infection, young donor age and chronic graft-versus-host disease in bone marrow allograft recipients. The Nordic Bone Marrow Transplantation Group. Bone Marrow Transplant 1990; 6: 413-418. (Pubitemid 20344124)
19. Craddock C, Szydlo RM, Dazzi F, Olavarria E, Cwynarski K, Yong A et al. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis. Br J Haematol 2001; 1: 228-236. (Pubitemid 32151176)
20. Hagglund H, Bostrom L, Remberger M, Ljungman P, Nilsson B, Ringden O. Risk factors for acute graft-versus-host disease in 291 consecutive HLA-identical bone marrow transplant recipients. Bone Marrow Transplant 1995; 6: 747-753. (Pubitemid 26008431)
21. Hokland M, Jacobsen N, Ellegaard J, Hokland P. Natural killer function following allogeneic bone marrow transplantation. Very early reemergence but strong dependence of cytomegalovirus infection. Transplantation 1988; 6: 1080-1084.
22. Devaud C, Bilhere E, Loizon S, Pitard V, Behr C, Moreau JF et al. Antitumor activity of gammadelta T cells reactive against cytomegalovirus- infected cells in a mouse xenograft tumor model. Cancer Research 2009; 9: 3971-3978.